[Biological treatment of rare inflammatory rheumatic diseases].
The current status of the use of biological medicine in the treatment of adult onset morbus still, Wegeners granulomatosis and systemic lupus erythematosus (SLE) is reviewed. The need for controlled trials is emphasized. Anti-CD20 treatment for SLE patients with kidney involvement and patients with Wegeners granulomatosis seems promising. Anti-TNF and IL1 receptor antagonist can control disease activity in most patients with adult morbus still.
Baslund
Bo
B
Rigshospitalet, Reumatologisk Klinik TA, København Ø. bbaslund@gmail.com
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D016706:Still's Disease, Adult-Onset / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D018501:Antirheumatic Agents; D007155:Immunologic Factors; D017472:Receptors, Interleukin-1; D014409:Tumor Necrosis Factor-alpha